Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026

Silexion Therapeutics Corp

2025-Q3 EPS reported $10.36

Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.
Cash and equivalents $9.2M as of Sep 30, up from $1.2M at Dec 2024, after raising ~$9.5M in Q3.
R&D spend $2.2M (-31% YoY); G&A $1.1M (-77% YoY); shareholders' equity improved to $7.0M.
Phase 2/3 trial of SIL204 in KRAS-driven cancers on track for H1 2026; regulatory submissions planned for Q4 2025/Q1 2026.
New preclinical data shows SIL204 efficacy across five cancer types, including first gastric cancer evidence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.